Trial Profile

A randomized, multi-centre neoadjuvant study in high-risk, resectable Stage III melanoma, evaluating MDNA11 in combination with nivolumab, with or without ipilimumab

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Feb 2026 According to a Medicenna Therapeutics media release, company anticipates sharing interim clinical data from this study in neoadjuvant melanoma in H2 2026.
15 Jan 2026 According to a Medicenna Therapeutics media release, this trial is being conducted In collaboration with the Fondazione Melanoma Onlus.
15 Jan 2026 According to a Medicenna Therapeutics media release, the company expects to initiate this trial in H1 2026 with interim data readouts in H2 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com